Alzheimer's Disease Market to Experience Decline, Forecasts GBI Research27 Mar 2013 • by Natalie Aster
A highly dynamic market scenario is expected in neurodegenerative diseases over the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer's disease (AD) has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. However, the market for Parkinson's disease is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US even though it will soon hit its own patent cliff.
In spite of a number of high-profile clinical trial failures such as bapineuzumab and, to an extent, solanezumab for the treatment of AD, the overall pipeline for neurodegenerative diseases remains strong. It contains an estimated 678 pipeline products, most of which are being developed for the treatment of AD or Parkinson's disease (PD). There are relatively few products in Phase III development, although Phases I and II are relatively populated with a variety of molecules. The largest stage of development in terms of the number of molecules is the preclinical stage, which accounts for 42% of the pipeline with 288 molecules identified at this stage.
The report "Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff" by GBI Research provides analysis on the current therapeutic environment in the treatment of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and Amyotrophic lateral sclerosis (ALS) across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan. The report provides market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations. Important Mergers and Acquisitions (M&As) as well as co-development and licensing agreements are covered along with key market barriers and drivers.
Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff
Published: March, 2013
Price: US$ 3,500.00
More information can be found in the report “Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff” by GBI Research.
To order the report or ask for sample pages contact firstname.lastname@example.org